A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension to Demonstrate the Efficacy and Safety of Desmopressin Orally Disintegrating Tablets for the Treatment of Nocturia in Adult Males

Trial Profile

A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension to Demonstrate the Efficacy and Safety of Desmopressin Orally Disintegrating Tablets for the Treatment of Nocturia in Adult Males

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Nov 2016

At a glance

  • Drugs Desmopressin (Primary)
  • Indications Nocturia
  • Focus Registrational; Therapeutic Use
  • Sponsors Ferring Pharmaceuticals
  • Most Recent Events

    • 01 Nov 2016 According to Ferring Pharmaceuticals media release, based on the result of this trial, NOQDIRNA (oral lyophilisate desmopressin) has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA).
    • 03 May 2016 According to a Ferring Pharmaceuticals media release, NOCDURNA was reviewed via the Decentralised Procedure (DCP) with the Swedish Medical Products Agency (MPA) acting as the Reference Member State (RMS) in the European union.
    • 03 May 2016 According to a Ferring Pharmaceuticals media release, desmopressin [Nocdurna] has been approved in the European Union for the symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top